Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U4EU
|
|||
| Former ID |
DCL000224
|
|||
| Drug Name |
SB-743921
|
|||
| Synonyms |
N-[1-(3-benzyl-7-chloro-4-oxo-quinazolin-2-yl)propyl]-4-bromo-N-(3-dimethylaminopropyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C31H34Cl2N2O3
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C.Cl
|
|||
| InChI |
1S/C31H33ClN2O3.ClH/c1-20(2)28(34(17-7-16-33)31(36)23-12-10-21(3)11-13-23)30-26(18-22-8-5-4-6-9-22)29(35)25-15-14-24(32)19-27(25)37-30;/h4-6,8-15,19-20,28H,7,16-18,33H2,1-3H3;1H/t28-;/m1./s1
|
|||
| InChIKey |
MLMZVWABFOLFGV-LNLSOMNWSA-N
|
|||
| CAS Number |
CAS 940929-33-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Kinesin-like protein KIF11 (KIF11) | Target Info | Inhibitor | [3] |
| Reactome | MHC class II antigen presentation | |||
| Kinesins | ||||
| WikiPathways | MHC class II antigen presentation | |||
| Kinesins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00343564) A Study of SB-743921 in Non-Hodgkin's Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54. | |||
| REF 3 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.